Profiel
Dean A.
Falb worked as Vice President-Research & Development at Stryker Corp.
from 2005 to 2012.
He also worked as Senior Vice President-Research & Development at Praecis Pharmaceuticals, Inc. and as Chief Scientific Officer at LogicBio Therapeutics, Inc. In 2013, he became the Chief Technology Officer at Synlogic, Inc. Dr. Falb holds a doctorate degree from Harvard University and an undergraduate degree from Purdue University.
Eerdere bekende functies van Dean A. Falb
| Bedrijven | Functie | Einde |
|---|---|---|
| SYNLOGIC, INC. | Hoofd Techniek/Wetenschap/O&O | 01-05-2018 |
| STRYKER CORPORATION | Hoofd Techniek/Wetenschap/O&O | 01-01-2012 |
| LOGICBIO THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | - |
Praecis Pharmaceuticals, Inc.
 Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA. | Hoofd Techniek/Wetenschap/O&O | - |
Opleiding van Dean A. Falb
| Harvard University | Doctorate Degree |
| Purdue University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| SYNLOGIC, INC. | Health Technology |
| STRYKER CORPORATION | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Praecis Pharmaceuticals, Inc.
Praecis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Praecis Pharmaceuticals, Inc. develops drugs and therapies for the treatment of cancer. The firm also develops peptide-based drugs. The company was founded 1993 and is headquartered in Waltham, MA. | Health Technology |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
